Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | RPA1 | P27694 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2098325 | 0.82 | MAPT (0.41) | PNMTTAAR1MAPTHTTIDO1 | |
| SCHEMBL1503218 | 0.79 | PIK3CA (0.45) | PIK3CADAOPNMTTAAR1HDAC3 | |
| SCHEMBL16388285 | 0.79 | PIK3CA (0.45) | PIK3CADAOPNMTTAAR1HDAC3 | |
| SCHEMBL2172166 | 0.78 | PIK3CA (0.45) | PIK3CADAOSLC2A1PNMTTAAR1 | |
| SCHEMBL622755 | 0.78 | IDO1 (0.58) | PNMTTAAR1HTTTSHRIDO1 | |
| SCHEMBL1547893 | 0.78 | HTT (0.45) | DAOHTTALDH1A1MAOB | |
| SCHEMBL8220202 | 0.77 | PIK3CA (0.44) | PIK3CADAOPNMTTAAR1HDAC3 | |
| SCHEMBL257081 | 0.77 | TSHR (0.44) | PIK3CADAOPNMTTAAR1HDAC3 | |
| SCHEMBL151278 | 0.77 | PIK3CA (0.44) | PIK3CADAOSLC2A1PNMTTAAR1 | |
| SCHEMBL42421 | 0.77 | CSNK2A1 (0.50) | PIK3CAPNMTTAAR1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | claimed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | claimed |
| WO-2008077651-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS INC (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3681871-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | Azevan Pharmaceuticals, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| WO-2007109615-A2 | β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS | AZEVAN PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-7268125-B2 | β-lactamyl vasopressin V1a antagonists | AZEVAN PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20060281728-A1 | 3-Substituted beta-lactamyl vasopressin v1a antagonists | AZEVAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | disclosed |
| US-7119083-B2 | β-Lactamyl vasopressin V1a Antagonists | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-28 | — | — | US | disclosed |
| WO-2006102308-A2 | BETA-LACTAMYL VASOPRESSIN V1B ANTAGONISTS | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060166925-A1 | Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2006-07-27 | — | — | US | disclosed |
| WO-2005035492-A1 | 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | SERENIX PHARMACEUTICALS, LLC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050043328-A1 | Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EPERIMENTALNI BOTANIKY AKADEMI VED CESKE REPUBILIKY (CZ) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | PIK3CA 2314/4885DAO 1541/4885SLC2A1 3471/4885 |
| US-20060166925-A1 | Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | ADAR, ADORA2A, AMPD2 | PIK3CA 741/4885DAO 737/4885SLC2A1 4006/4885 |
| US-20050043328-A1 | Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | ATIC, UMPS, CCNB1 | PIK3CA 623/4885DAO 896/4885SLC2A1 4475/4885 |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | AVPR1A, AVPR2, AVPR1B | PIK3CA 3101/4885DAO 252/4885SLC2A1 2782/4885 |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | GPX4, CRH, TXN | PIK3CA 3381/4885DAO 1309/4885SLC2A1 2396/4885 |
| US-20060281728-A1 | 3-Substituted beta-lactamyl vasopressin v1a antagonists | AVPR1A, AVPR2, AVPR1B | PIK3CA 3442/4885DAO 191/4885SLC2A1 2973/4885 |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | PIK3CA 2314/4885DAO 1541/4885SLC2A1 3471/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | PIK3CA 3378/4885DAO 1919/4885SLC2A1 2590/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | PIK3CA 3378/4885DAO 1919/4885SLC2A1 2590/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | PIK3CA 2314/4885DAO 1541/4885SLC2A1 3471/4885 |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PNP | PIK3CA 1550/4885DAO 44/4885SLC2A1 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.